Warfarin in the presence of chronic atrial fibrillation |
4.00 |
2.91-5.09 |
EG1: Totally disagreed, but did not provide comment |
3.86 |
3.03-4.69 |
Aspirin in the presence of chronic atrial fibrillation, where warfarin is contraindicated, but aspirin is not |
4.13 |
2.99-5.23 |
EC2: Aspirin in the presence of chronic atrial fibrillation in patients with CHADS2 less than 2, when warfarin is contraindicated, but aspirin is not. If CHADS2 is less than or equal to 2, aspirin is clearly inferior to warfarin. Before choosing to prescribe aspirin, other non-contraindicated anticoagulants must be evaluated. Comment EG1: Currently, thrombin inhibitors and factor X inhibitors have been shown to be equal or superior to warfarin in elderly patients with preserved renal function and a creatinine clearance over 30 |
3.86 |
2.31- 5.41 |
Aspirin or clopidogrel with a documented history of coronary, cerebral or peripheral vascular disease in patients in sinus rhythm |
4.38 |
3.20-5.55 |
EG1: Totally disagreed, but did not provide comments |
4.57 |
4.08-5.01 |
Antihypertensive therapy where systolic blood pressure is consistently greater than 160 mm Hg |
4.75 |
4.36-5.14 |
- |
- |
- |
Statin therapy in patients with a documented history of coronary, cerebral or peripheral vascular disease, where the patients' "functional status" remains independent for activities of daily living and life expectancy is more than 5 years |
4.38 |
3.94-4.81 |
EC2: This would not differentiate the population. The evidence of long-term benefits of statins in cerebral or peripheral arterial atherosclerotic disease is weaker than the evidence supporting statin use in coronary disease, but the majority agree that therapy must be introduced, especially if LDL-C is over 100 mg/dl |
4.43 |
3.93-4.92 |
Angiotensin-converting enzyme inhibitor therapy in chronic heart failure. |
4.75 |
4.36-5.14 |
- |
- |
- |
Angiotensin-converting enzyme inhibitor therapy following acute myocardial infarction |
4.63 |
4.19-5.06 |
- |
- |
- |
Beta-blocker therapy in chronic stable angina |
4.50 |
4.05-4.95 |
- |
- |
- |
Metformin with type 2 diabetes or metabolic syndrome (in the absence of renal impairment) |
4.88 |
4.58-5.17 |
- |
- |
- |
Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy in diabetes with nephropathy, i.e. overt proteinuria, microalbuminuria on urinalysis (higher than 30 mg/24 h) or renal impairment |
4.00 |
- |
- |
- |
- |
Statin therapy in diabetes mellitus if one or more cardiovascular risk factors are present |
4.63 |
4.19-5.06 |
- |
- |
- |
Antiplatelet therapy in diabetes mellitus if one or more cardiovascular risk factors are present (hypertension, hypercholesterolemia, history of smoking) |
4.50 |
4.05-4.95 |
- |
- |
- |
Regular inhaled ß-2 agonist or anticholinergic agent for mild to moderate chronic obstructive pulmonary disease |
4.25 |
3.86-4.64 |
EG4: Attempt to assay beta-2 antagonist by evaluating the weight of fragile elderly. There are reports of increased osteoporosis induced by long-term use of corticosteroid, even in inhalation therapy. At this point, there are controversies. EG6: Attempt for patients with cognitive deficits who may not be able to use inhaler devices |
4.00 |
3.08-4.92 |
Regular inhaled steroid therapy in moderate-to-severe asthma or chronic obstructive pulmonary disease, where the forced expiratory volume in one second is less than 50% |
4.88 |
4.58-5.17 |
- |
- |
- |
Home continuous oxygen, where chronic type 1 respiratory failure (pO2 < 60 mm Hg; pCO2 < 48.75 mm Hg) or type 2 respiratory failure (pO2 < 60 mm Hg; pCO2 > 48.75 mm Hg) was documented |
4.50 |
4.05-4.95 |
- |
- |
- |
L-DOPA in idiopathic Parkinson's disease with definite functional impairment and resultant disability |
5.00 |
- |
- |
- |
- |
Antidepressants in the presence of moderate-to-severe depressive symptoms in the past three months |
4.86 |
4.51-5.21 |
- |
- |
- |
Disease-modifying anti-rheumatic drugs (DMARDs) with moderate to severe active disease in the past 12 weeks |
4.63 |
4.19-5.03 |
- |
- |
- |
Bisphosphonates in patients using oral glucocorticoid maintenance therapy |
4.25 |
3.38-5.12 |
EG3, EG4 and EG6: Evaluate bone densitometry. Pay attention to osteomalacia |
2.86 |
1.22-4.50 |
Calcium and vitamin D supplementation in patients with known osteoporosis (radiological evidence, previous fragility fracture or dorsal kyphosis) |
4.63 |
3.74-5.51 |
EG3: Some studies show that vitamin D intake does not interfere with bone density |
4.71 |
4.26-5.17 |
Proton pump inhibitors in the presence of severe gastroesophageal acid reflux or peptic stricture requiring dilatation |
4.80 |
4.24-5.36 |
- |
- |
- |
Fiber supplementation for chronic, symptomatic diverticular disease with constipation |
4.60 |
3.92-5.28 |
EG6: If the patient is able to consume an adequate fluid intake |
5.0 |
- |